Last updated: 11/07/2018 14:39:25
A Double-Blind, Parallel Group Placebo-Controlled Study to Determine the Effects of Rosiglitazone on Insulin Resistance and Glucose Tolerance When Administered to Subjects with Impaired Glucose Tolerance.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Double-Blind, Parallel Group Placebo-Controlled Study to Determine the Effects of Rosiglitazone on Insulin Resistance and Glucose Tolerance When Administered to Subjects with Impaired Glucose Tolerance.
Trial description: A Double-Blind, Parallel Group Placebo-Controlled Study to Determine the Effects of Rosiglitazone on Insulin Resistance and Glucose Tolerance When Administered to Subjects with Impaired Glucose Tolerance.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Bennett SMA, Jones NP, Agrawal A, et al. Rosiglitazone improves insulin sensitivity and 24-hr ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetologia 2001; 44 (Suppl 1):A200. Abs 770 presented at EASD 2001.
Bennett SMA. Manuscript accepted in Diabetic Medicine. Publication early 2004.
Elasha H, Agrawal A, Jones NP, et al. Rosiglitazone improves glycaemic and insulinaemic responses in subjects with impaired glucose tolerance. Diabetologia 2001; 44 (Suppl 1):A221. Abs 851 presented at EASD 2001.
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Bennett, S. M., Agrawal, A., Elasha, H., Heise, M., Jones, N. P., Walker, M., and Wilding, J. P. Diabet Med 2004; 21(5):415-22
Medical condition
Diabetes Mellitus, Type 2
Product
rosiglitazone
Collaborators
Not applicable
Study date(s)
September 1997 to June 2000
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2000-16-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website